The Quiet Consolidation of Gut Health
Private equity has spent the last decade rolling up dental practices, dermatology clinics, and urgent care centers. Now it has turned its attention to gastroenterology – a specialty that generates steady, recurring revenue through colonoscopies, endoscopies, and chronic disease management. Regional GI practices, many of them built over decades by physician-owners, are selling to PE-backed platforms at a pace that would have seemed unlikely five years ago.
The math is straightforward: a well-run GI practice with multiple physicians, an in-house ambulatory surgery center, and a loyal patient base is a cash-generating machine. Procedure volume is predictable. Insurance reimbursements, while always under some pressure, are not as volatile as in primary care. And an aging population means demand for colorectal screenings and digestive disorder treatment is only growing.
What makes this wave different from earlier healthcare rollups is how quietly it is happening.
How the Deal Structure Works
PE firms typically approach GI practices through a platform acquisition – buying one established group, then using it as a base to absorb smaller regional practices through add-on deals. The selling physicians usually receive a lump-sum payment for their equity stake and are asked to sign long-term employment agreements, often three to five years, with production-based compensation tied to procedure and patient volume. Some deals include a second “bite of the apple,” meaning physicians receive additional payouts if the consolidated platform is eventually sold at a higher valuation to a larger buyer or taken public.
The ambulatory surgery center attached to a practice is often the most valuable asset in the transaction. These centers allow GI physicians to perform procedures outside of hospitals, capturing facility fees that would otherwise go to hospital systems. PE acquirers understand this clearly – the ASC is frequently valued separately from the clinical practice itself, and maintaining or expanding ASC capacity is central to most rollup growth strategies. A practice with three physicians and no surgery center is worth considerably less than a comparable group that controls its own procedure facility.
Sellers are often motivated by more than just retirement planning. Administrative burden has increased sharply for independent practices over the past several years – prior authorization requirements, electronic health record compliance costs, billing complexity, and staff recruitment all consume time and money that smaller groups struggle to absorb. Selling to a PE-backed platform offloads much of that infrastructure burden while allowing physicians to focus on patient care, at least in the near term.
What Physicians Are Giving Up
The tradeoff is real and not always apparent until after closing. Physician-owners who sell lose direct control over hiring decisions, scheduling, staffing ratios, and vendor contracts. Compensation structures that seemed generous at signing can become sources of friction when production targets tighten or overhead allocations shift in ways the employment agreement did not anticipate. Some physicians who sold to early rollup platforms have reported that the practice culture changed noticeably within the first 18 months, with more administrative oversight and greater pressure on throughput.
There is also the question of patient continuity. PE-owned platforms have an incentive to maximize volume, which can translate to shorter appointment slots, higher patient loads per physician, and reduced time for complex case discussions. For a specialty like gastroenterology – where patients with Crohn’s disease, ulcerative colitis, or Barrett’s esophagus require long-term, relationship-based care – that pressure is not trivial. The specialty’s value has always depended partly on the physician knowing the patient’s full history across years of treatment.
This pattern is not unique to GI. Regional medical billing firms have faced comparable dynamics when absorbed into larger platforms – operational efficiencies are real, but so are the cultural and structural losses that come with consolidation. The physicians who fare best in PE-owned environments tend to be high-volume proceduralists who were already running their practices like businesses, with less attachment to the autonomy that drew many into independent practice in the first place.
Who Is Buying and What Comes Next
Several PE-backed GI platforms have been actively building scale across multiple states. The strategy follows a familiar private equity playbook: acquire enough regional groups to create a network with negotiating leverage over insurers, standardize back-office operations to reduce costs, and position the combined entity for a sale to a strategic buyer – typically a hospital system, a larger PE fund, or a publicly traded physician management company – within five to seven years.
Hospital systems are watching this consolidation with a mixture of concern and interest. Independent GI practices have historically been referral sources for hospitals. As those practices move under PE ownership, referral patterns can shift, and the hospital relationship that once operated on goodwill and informal reciprocity becomes a formal contractual negotiation. Some hospital systems have responded by acquiring GI groups themselves, unwilling to cede the specialty to outside capital.
For the physicians still deciding whether to sell, the window that makes these deals attractive may not stay open indefinitely. Reimbursement pressure from Medicare and commercial payers is real. Staffing costs have risen. And if enough regional competitors in a given market sell to the same platform, holding out as an independent becomes harder – not because the practice fails, but because the PE-owned competitor has enough scale to negotiate better contracts, recruit aggressively, and absorb losses that a smaller independent cannot. The physician who waits may still get a deal, just not the same one available today.
